$STTK

Shukla Abhinav A. sold $166K of STTK

Shukla Abhinav A. (Chief Technical Officer) sold 23,465 shares of Shattuck Labs, Inc. (STTK) at an average of $7.08 ($7.07–$7.08, $0.17M total) across 2 trades over 2026-06-30 to 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shukla Abhinav A.
Published Jul 3, 2026, 12:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 3, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STTK
Neutral
high confidence
Mentioned
$STTK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STTKNeutralLow
01

Why it matters

A CTO open-market sale of ~$166k occurred across two trades, explicitly under a pre-arranged 10b5-1 plan, with no other company-specific news included.

02

Market read

Traders may monitor for sentiment impact, but the 10b5-1 framing reduces the likelihood of a fundamental read-through.

03

What to watch

The article provides sale size and price range but no context on total insider holdings, tax planning, or whether other insiders also sold/bought around the same period.

Relevance 3/10Novelty 3/10Timing: Immediately after the Form 4 filing (filed 2026-07-02) for near-term sentiment checks.

Background

The article is a SEC Form 4 insider transaction disclosure for Shattuck Labs, Inc. (STTK).

Company-level read

Ticker impact

$STTKNeutralHigh confidence
Context

Shattuck Labs insider (CTO) filed a Form 4 open-market sale of 23,465 shares at ~$7.08 during 2026-06-30 to 2026-07-01.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is a Form 4 sale (not a buy), explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change.

Market effects

Minimal; single-company insider transaction without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Insider sales under 10b5-1 can be purely liquidity-driven, so the signal may be closer to neutral than negative.

Key entities

  • Shattuck Labs, Inc.

    Issuer of the Form 4 insider transaction; subject of the filing.

  • Shukla Abhinav A.

    Chief Technical Officer who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STTKMed

Strattec Security Corporation Q4 2026 Earnings Call Summary

Strattec Security Corporation reported record annual revenue of $579.4 million for 2026, driven by pricing, cost actions, and operational improvements. The company reorganized its product portfolio and realized $6 million in restructuring savings, expanding gross margin to 16.5%. Strattec anticipates a challenging 2027 with a 2% decline in North American production and targets long-term gross margins of 18% to 20%. The company maintains a debt-free balance sheet with $108.2 million in cash and p

$STTKMed

Shattuck Labs Jumps as Two Analysts Start Bullish Coverage

Shattuck Labs (STTK) rose 4.91% after two analysts initiated coverage with positive ratings. TD Cowen rated it buy, while Raymond James gave a strong buy and $18 price target. Both highlighted SL-325, a drug candidate for inflammatory bowel disease, citing its novel mechanism. The company reported $208.3M in cash and expects funding into 2029. Phase 2b trial for SL-325 is set to start in Q3.

$STTKMed

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

$STTKMed

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent

Shattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A bi